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We used exome sequencing to identify the genetic basis of combined malonic and methylmalonic aciduria (CMAMMA). We sequenced the exome of an individual with CMAMMA and followed up with sequencing of eight additional affected individuals (cases). This included one individual who was identified and diagnosed by searching an exome database. We identify mutations in ACSF3, encoding a putative methylmalonyl-CoA and malonyl-CoA synthetase as a cause of CMAMMA. We also examined a canine model of CMAMMA, which showed pathogenic mutations in a predicted ACSF3 ortholog. ACSF3 mutant alleles occur with a minor allele frequency of 0.0058 in ~1,000 control individuals, predicting a CMAMMA population incidence of ~1:30,000. ACSF3 deficiency is the first human disorder identified as caused by mutations in a gene encoding a member of the acyl-CoA synthetase family, a diverse group of evolutionarily conserved proteins, and may emerge as one of the more common human metabolic disorders.
Methylmalonic acidemias (MMAemias) are heterogeneous disorders that show elevated methylmalonic acid (MMA) in body fluids. Deficiency of methylmalonyl-CoA mutase (MUT) or the enzymes (MMAA, MMAB and MMADHC) that synthesize 5′-adenosylcobalamin comprise most disease subtypes. Some affected individuals have atypical forms of MMAemia that lack enzymatic and molecular definition, for example, CMAMMA. CMAMMA was first reported in a child with immunodeficiency, failure to thrive, seizures, increased urinary MMA compared to malonic acid (MA) and normal malonyl-CoA decarboxylase activity 1 . A Labrador retriever with similar biochemical features and neurodegeneration has also been described 2 .
To determine the cause of CMAMMA, we took a multifaceted approach that included exome and candidate gene sequencing in nine affected subjects, identification of the canine ortholog and mutation analysis in an affected dog, and a new strategy of hypothesisgenerating clinical research in an exome cohort 3 . We establish ACSF3 mutations as a cause of CMAMMA and describe the first disease association with a member of the acyl-CoA synthetase (ACS) family, which is comprised of enzymes that activate fatty acids for intermediary metabolism 4 .
Nine subjects with CMAMMA participated, and six of them were evaluated at the US NIH. The age of diagnosis and symptoms among the subjects were variable ( Table 1) . After uneventful early decades, four subjects were diagnosed in adulthood with neurological manifestations (seizures, memory problems, psychiatric disease and/or cognitive decline) without vitamin B12 deficiency. Five subjects presented during childhood with symptoms suggestive of an intermediary metabolic disorder (coma, ketoacidosis, hypoglycemia, failure to thrive, elevated transaminases, microcephaly, dystonia, axial hypotonia and/or developmental delay).
Methylmalonic and malonic aciduria with urinary MMA/MA > 5 was present in seven of the nine subjects ( Table 1 ). The characteristic pattern of biochemical and genetic testing results in these subjects showed elevated serum MMA but normal serum B12, acylcarnitines, total homocysteine, malonyl-CoA decarboxylase activity, 1-C 14propionate incorporation, malonyl-CoA decarboxylase (encoded by MLYCD) genetic testing, and sequencing of known MMAemia genes ( Table 1 ). We measured plasma MA using gas chromatographymass spectrometry (GC/MS) in six subjects; the plasma MA levels in these six subjects were markedly elevated ( Table 1) . We conclude Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria 8 8 4 VOLUME 43 | NUMBER 9 | SEPTEMBER 2011 Nature GeNetics l e t t e r s that these subjects all have the same form of CMAMMA, which is distinct from other types of MMAemia and malonyl-CoA decarboxylase deficiency.
For subject 1, we sequenced target-selected libraries in the paired-end 101-bp configuration, which yielded 114,467 variant genotypes. We used genetic filters for homozygosity or compound heterozygosity. We included nonsynonymous, splice, frameshifting and nonsense variants as potential mutations but excluded dbSNP variants. We used control exome data 3 to exclude homozygous variants or variants with >10% frequency (Supplementary Table 1 and Online Methods).
The filtering strategy yielded 12 genes, from which we selected for further evaluation ACSF3, encoding an orphan member of the acyl-CoA synthetase family, based on its putative function and predicted mitochondrial localization. We found three ACSF3 exome variants in subject 1 (c.1385A > C (p.Lys462Thr), c.del1394_1411 (p.Gln465_ Gly470del) and c.1627C > T (p.Arg558Trp)) and confirmed them by Sanger sequencing ( Table 1 , Supplementary Fig. 1 and Supplementary Table 2 ). The variants p.Lys462Thr and p.Gln465_Gly470del were in trans with p.Arg558Trp based on parental genotypes and segregated in two unaffected siblings who, like their parents, had normal serum MMA levels. We sequenced ACSF3 exons in seven additional subjects with CMAMMA and six had ACSF3 variations ( Table 1 , Supplementary Fig. 1 ). In one subject, we detected no damaging mutations.
Next, we identified a putative canine ACSF3 ortholog and sequenced DNA from a Labrador retriever with CMAMMA 2 ; this analysis showed a homozygous alteration (c.1288G > A (p.Gly430Ser); orthologous to human p.Gly480) in a conserved residue ( Fig. 1, Table 1 and Supplementary Fig. 1 ). This variant was absent in 40 control Labrador DNAs selected for maximum diversity based on American Kennel Club numbers. Finally, we took a new approach to discover affected individuals by analyzing the exome data of 401 individuals ascertained for cardiovascular phenotypes 3 . We identified a 66-year-old female, apparently homozygous for a c.1411C > T (p.Arg471Trp) ACSF3 variant. This individual had no known metabolic disease symptoms but reported incontinence and mild memory problems. Her laboratory evaluation showed 48 µM MMA and 11.3 µM MA in plasma and 206 mmol/mol Cr MMA and 26.3 mmol/mol Cr MA in urine and normal serum B12 levels and acylcarnitines. We did not find mutations in other known MMAemia genes or MLYCD in her exome ( Table 1) . . l e t t e r s
We identified nine missense mutations, one in-frame deletion and one nonsense mutation (Fig. 1) . Four subjects were apparently homozygous for ACSF3 variants. Although it is possible that unidentified deletions might play a role in this disorder, it is unlikely for these individuals ( Table 1 ). Most of the variants resided in the C-terminal half of ACSF3. Eight out of nine missense mutations and the in-frame deletion were located in conserved ACS motifs predicted to be involved in AMP binding (motif I), conformational change and catalytic function (motif II), substrate binding (motifs III and IV) or catalysis (motif V) 5 (Fig. 1) . Protein analyses using fibroblasts from subjects 1-4 and subject 7 showed the presence of cross-reactive ACSF3 (Supplementary Fig. 2) . Fibroblasts from subjects 1-4 produced 2.4-fold to sixfold more MMA than control cells ( Fig. 2a) after chemical stimulation. Viral expression of ACSF3 but not GFP (Fig. 2b) restored metabolism and provided validation of ACSF3 function in a cell culture biochemical assay.
These data establish a candidate gene for CMAMMA using exome sequencing in a single trio with validation using four approaches. First, seven additional probands harbored two mutations in ACSF3. Second, an affected dog had a single, unique sequence variant in the canine ACSF3 ortholog in a conserved residue that was absent in 40 diverse controls. Third, we identified one subject with two ACSF3 mutations in a cohort of subjects not ascertained for metabolic disease who had biochemical features of CMAMMA. Finally, viral complementation of ACSF3 in subject fibroblasts corrected the cellular metabolic defect. Based on these observations, we conclude that mutations in ACSF3 cause CMAMMA.
ACSF3 is an orphan member of the acyl-CoA synthetase gene family, which contains genes that encode enzymes that thioesterify substrates into CoA derivatives and weakly activated C24:0 fatty acid 4 . The biochemical abnormalities in the subjects led us to reassess the possible function of ACSF3. When we compared human ACSF3 to Bradyrhizobium japonicum malonyl-CoA synthetase (MCS), a well-characterized enzyme, the proteins were more identical (32%) and similar (50%) to each other than ACSF3 was to the next closest human ACS family member (ACSM3v1, 28% identity). Phylogenetic analyses rooted human ACSF3 with the MCS enzymes and not other ACSs (Supplementary Fig. 3) . To provide preliminary experimental evidence for predicted function, we examined purified, glutathione S-transferase (GST)-tagged ACSF3 under MCS assay conditions and found that the enzyme activated malonate and methylmalonate, but not acetate, into the respective coenzyme thioesters (Supplementary Table 3 ). The specific activity of GST-tagged ACSF3 was higher with malonate as a substrate compared to methylmalonate, similar to its prokaryotic homologs. Because the first 59 amino acids of ACSF3 are predicted to be a mitochondrial leader sequence ( Supplementary  Fig. 4) , we performed immunostaining with fibroblasts overexpressing ACSF3 and a C-terminal GFP-ACSF3 fusion protein to experimentally validate the subcellular localization. ACSF3 staining showed a distinct mitochondrial distribution and co-localized with a mitochondrial antibody (Fig. 3) . The comparative sequence analysis, enzymatic data and subcellular localization lead us to propose that ACSF3 is a mitochondrial methylmalonyl-CoA and MCS, an enzyme postulated to catalyze the first step of intramitochondrial fatty acid synthesis 5 .
The assignment of ACSF3 as an MCS provides a framework to understand the consequences of the ACSF3 alterations and the metabolic perturbations of CMAMMA. MCS from Rhizobium trifolii and B. japonicum activate malonate and methylmalonate as substrates in vitro 6, 7 , as does ACSF3 (Supplementary Table 3 ), suggesting that malfunction of this enzyme causes accretion of the proximal substrates that manifests as methylmalonic and malonic aciduria. Sitedirected mutagenesis experiments with B. japonicum MCS showed that p.Glu308Gln abolishes malonate binding 7 . The corresponding human ACSF3 position is the residue altered in subject 3, p.Glu359Lys in motif III, which predicts that this mutation is likely to effect the Figure 1 Alignment of the motif regions in ACSF3 orthologs and the malonyl-CoA synthetase enzymes in bacteria. We aligned the sequences with MegAlign using the Clustal W method (Online Methods). An additional three amino acids N-terminal to motif I are shown. We aligned motif II independent of the full-length protein to improve the alignment of the ACSF3 and MCS proteins. The ACSF3 alterations identified in the eight subjects and affected dog are indicated. The asterisk indicates the dog variant p.Gly430Ser, which is orthologous to position p.Gly480 in human ACSF3. Michaelis constant (K m ) for malonate. Arg471 in motif II is nearly invariant in the ACS family 4 and is essential for acyl-CoA synthetase activity [8] [9] [10] . Therefore, an Arg471 alteration in ACSF3, as was present in subjects 5 and 6, likely affects enzymatic function. Other missense alterations (p.Pro243Leu, p.Thr358Ile, p.Gly430Ser (in dog) and p.Arg558Trp) map to conserved residues in B. japonicum and Rhizobium leguminosarum MCS (Fig. 1) or to conserved residues in other ACSF3 family members (p.Met198Arg and p.Lys462Thr) and are likely to be deleterious. In the ClinSeq cohort (see URLs), there were an additional four participants heterozygous for ACSF3 variants (p.Glu359Lys, n = 1 and p.Arg558Trp, n = 3) also found in individuals with CMAMMA. In the 1000 Genomes Project dataset (see URLs; 20100804 release, with an estimated coverage of 629 genomes) there were six individuals with ACSF3 alterations observed in our cohort (p.Glu359Lys, n = 1 and p.Arg558Trp, n = 5). Combining these data yielded an overall minor allele frequency of 0.0058 (95% CI 0.0033-0.0106) for an estimated disease incidence of ~1/30,000 (95% CI 1/9,000-1/92,000). We predict that ACSF3 deficiency is one of the most common forms of MMAemia 11 , and perhaps, one of the most common inborn errors of metabolism. Clearly, the spectrum of symptoms and natural history of this disorder are highly variable and require further delineation. The identification of an affected individual using exome sequencing highlights a new and alterative diagnostic approach because ACSF3 deficiency is not identified with routine newborn screening (using elevated propionylcarnitine [C3]). We speculate that ACSF3 deficiency and other metabolic disorders that escape early diagnosis could be identified using genomic techniques.
URLs. GeneReviews, http://www.ncbi.nlm.nih.gov/books/NBK1231/; ClinicalTrials, http://clinicaltrials.gov/; Phrap assembler, http://www. phrap.org/; HomoloGene, http://www.ncbi.nlm.nih.gov/homologene; MitoProtII, http://ihg.gsf.de/ihg/mitoprot.html; ClinSeq, http:// www.genome.gov/20519355; 1000 Genomes Project, http://www. 1000genomes.org/home.
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